Mary Cianfrocca, D.O., M.B.A.
- Medical Oncology
Areas of Expertise
- Breast Cancer
- Breast Cancer
My career has been dedicated to breast cancer and I've been most passionate about research to find better treatments and ultimately a cure.
Mary Cianfrocca, D.O., M.B.A., brings over 20 years of clinical, research and administrative expertise to City of Hope, where she serves as senior medical director of community practices.
A longtime expert in the research and treatment of breast cancer, Dr. Cianfrocca strives to bring her patients the best possible care while exploring the newest and most innovative treatments on the horizon, from targeted therapy to immunotherapy and much more.
Dr. Cianfrocca received her medical degree at Chicago College of Osteopathic Medicine and continued her training at Chicago’s Rush Presbyterian St. Luke’s Medical Center and Northwestern University. She also holds an M.B.A. from Arizona State University.
Dr. Cianfrocca joined City of Hope following nearly a decade in leadership roles at Banner MD Anderson Cancer Center in Arizona. She is passionate about raising public awareness of breast cancer prevention and early detection. She is a much sought-after spokesperson in the mass media.
Dr. Cianfrocca ardently believes in City of Hope’s multidisciplinary approach to cancer care, and she admires the “spirit of collaboration and teamwork, with the goal of providing the best and most compassionate care for all of our patients and their loved ones.”
- 2019-Present, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California
- 2019-Present, Senior Medical Director, Community Practices, City of Hope, Duarte, California
- 2018-2019, Oncology Physician Executive, Northwest Region
- 2016-2018, Regional Medical Director, Northwest Region, Banner MD Anderson Cancer Center, Gilbert, Arizona
- 2014-2019, Division Chief, Internal Medicine, Banner MD Anderson Cancer Center, Gilbert, Arizona
- 2012-2019, Medical Director, Clinical Cancer Genetics Program, Banner MD Anderson, Gilbert, Arizona
- 2011-2019, Director, Multidisciplinary Breast Program, Banner MD Anderson, Gilbert, Arizona
- 2011-2019, Additional Clinical Stewardship, Banner MD Anderson, Gilbert, Arizona
- 2004-2011, Breast Medical Oncologist, Northwestern University Feinberg School of Medicine, Chicago, Illinois
- 1999-2004, Breast Medical Oncologist, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia
- Breast Cancer
- 2017, Masters of Business Administration, W.P. Carey School of Business, Arizona State University, Tempe, Arizona
- 1989, Doctor of Osteopathy, Valedictory Honors Distinction, Chicago College of Osteopathic Medicine, Downers Grove, Illinois
- 1984, Loyola University, Chicago, Illinois
- 1996-1999, Hematology/Oncology Fellowship, Department of Medicine, Northwestern University, Chicago, Illinois
- 1993-1994, Chief Resident, Rush Presbyterian St. Luke’s Medical Center, Chicago, Illinois
- 1990-1993, Resident, Department of Internal Medicine, Rush Presbyterian, St. Luke’s Medical Center, Chicago, Illinois
- 1989-1990, Rotating Internship, Chicago Osteopathic Hospital, Chicago, Ilinois
- 2009, Subspeciality Recertification: Oncology
- 1999, American Board of Internal Medicine, Subspeciality Certification: Oncology
- 1993, American Board of Internal Medicine Diplomate
Cianfrocca M, Cooley TP, Lee J, et al. Angiogenesis inhibitor COL-3 in the treatment of AIDS-related Kaposi’s sarcoma: A phase I AIDS Malignancy Consortium Study, J Clin Oncol 20(1) 153-159, 2002.
Freedman G, Anderson PR, Goldstein LJ, Hanlon AL, Cianfrocca ME, Millenson MM, vonMehren M, Torosian M, Boraas M, Nicolau N, Patchefsky AS, Evers K. Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer 98(5) 918-925, 2003.
Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB. Phase I Trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer, 94: 1621-6, 2006.
Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 14:4484-90, 2008.
Kaklamani VG, Cianfrocca M, Ciccone J, et al. Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer. Biomarkers 15(2): 191-3, 2010.
Cianfrocca M, Lee S, Von Roenn J, et al. Randomized Trial of Paclitaxel versus Pegylated Liposomal Doxorubicin for Advanced Human Immunodeficiency Virus-associated Kaposi’s Sarcoma: Evidence for Symptom Palliation from Chemotherapy Cancer 116:3969-77, 2010.
Cianfrocca M, Lee S, Von Roenn J, et al. Pilot Study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virusassocaited Kaposi’s sarcoma.: an Eastern Cooperative Oncology Group (ECOG) andAIDS Malignancy Consortium (AMC) trial, Cancer Chemother Pharmacol Jan 5 (epub ahead of print) 2011.
Kaklamani VG, Siziopikou K, Scholtens D, Lacouture M, Gordon J, Uthe R, Meservey C, Hansen N, Khan SA, Jeruss JS, Bethke K, Cianfrocca M, Rosen S, Von Roenn J, Wayne J, Parimi V, Jovanovic B, Gradishar W. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat Feb 27 (epub ahead of print) 2011.
Kumthekar P, Grimm SA, Avram MJ, Kaklamani V, Helenowski I, Rademaker A, Cianfrocca M, Gradishar W, Patel J, Mulcahy M, McCarthy K, Raizer JJ. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J Neurooncol 2013 Apr;112(2):247-55. doi: 10.1007/s11060-013-1055-0. Epub 2013 Jan 25.
Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-postitive patients with cancer: AIDS Maligancy Consortium trial AMC 061. Cancer. 2014 Jan 28. Doi: 10.1002/cncr.
28554. (epub ahead of print) 2014.
28554. (epub ahead of print) 2014.
Margolese RM, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrazole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomized, double-blind, phase 3 clinical trial. Lancet, published online December 10, 2015.
Ganz PA, Cecchini RS, Julian TB, Margolese RM, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patientreported outcomes with anastrazole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomized, double-blind, phase 3 clinical trial. Lancet, published online December 10, 2015.
- Member, American Society of Clinical Oncology
- Fellow, American College of Physicians (F.A.C.P.)
- Member, American College of Healthcare Executives (A.C.H.E.)
- 2010, Fellowship, American College of Physicians
- 2009, Northwestern University Feinberg School of Medicine Teaching Award
- 1991, Intern of the Year, Rush Presbyterian St. Luke’s Medical Center
- 1989, Valedictorian, Graduating class Chicago College of Osteopathic Medicine